C1q/tumor necrosis factor related protein 6 (CTRP6) regulates the phenotypes of high glucose-induced gestational trophoblast cells via peroxisome proliferator-activated receptor gamma (PPARγ) signaling

Jin Zhang and Wen-Pei Bai

Department of Obstetrics and Gynaecology, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China

ABSTRACT
Multiple studies have confirmed that adipokines are compactly relevant to insulin resistance and participate in the pathogenesis of gestational diabetes mellitus (GDM). This paper aimed to study the effects of C1q/tumor necrosis factor related protein (CTRP6) on the phenotypes of trophoblast cells, covering cell proliferation, invasion and migration, and initially explore the mechanism. High glucose was used to induce trophoblast cells to establish an in vitro model. The expression levels of CTRP6 were firstly determined, and then the effects of CTRP6 knockdown on cell viability, apoptosis, migration and invasion were assessed using CCK8, TUNEL, wound healing, Transwell assays. Moreover, the role of peroxisome proliferator-activated receptor gamma (PPARγ), probable target of CTRP6, was evaluated through co-transfection with PPARγ overexpression vector. The results of the present study revealed that CTRP6 and PPARγ were both upregulated in high glucose-induced cells. And CTRP6 knockdown could significantly elevate the abilities of cell viability, migration and invasion, and avoid cell apoptosis. In addition, PPARγ overexpression was found to restrain the protective effects of CTRP6 knockdown on the above aspects, indicating CTRP6 played a role in trophoblast cells via inhibiting PPARγ expression. In conclusion, CTRP6 regulated the viability, migration and invasion of high glucose-induced gestational trophoblast cells through PPARγ signaling.

Introduction
Gestational diabetes mellitus (GDM) refers to normal glucose metabolism before pregnancy and abnormal glucose tolerance first discovered during pregnancy, which is one of the most familiar complications of pregnancy [1]. It is manifested as metabolic and endocrine disorders, including significant changes in the body fluid environment, such as alterations in the levels of adipokines and inflammatory cytokines [2]. As the alterations in the childbearing age, dietary patterns and lifestyles of contemporary women, the morbidity of GDM is increasing gradually [3]. After childbirth, the glucose tolerance of most pregnant women with GDM returned to normal, whereas a few would develop type 2 diabetes [4]. Moreover, several studies have identified that, compared with healthy pregnant women, the offspring of pregnant women with GDM are at a relatively higher risk of long-term complications such as obesity and diabetes [5]. It is generally believed that the pathogenesis of GDM is complex, which may be the result of multiple factors such as inflammatory factors, insulin resistance (IR), pancreatic β-cell function defects, genetics and environment [6]. Recently, considerable studies have indicated that some adipokines, such as leptin, adiponectin and visfatin, are compactly relevant to IR and participate in the pathogenesis of GDM [2,7,8].

C1q/tumor necrosis factor related protein is a newly discovered highly conserved adiponectin family consisting of 15 members (CTRP1-CTRP15) [9]. Therein, CTRP6 is widely expressed in a variety of tissues and organs, including adipose tissue, heart, brain and placenta [10]. It plays different roles in different physiological or pathological processes, and has been proven to be involved in inflammation, diabetes, and cardiovascular disease [11]. In addition, a previous study
revealed that CTRP6 could inhibit the proliferation, invasion and migration of squamous cell carcinoma cells [12]. And another study deemed that CTRP6 could inhibit the proliferation of vascular smooth muscle cells induced by platelet-derived growth factor-bb [13]. Furthermore, knockout of CTRP6 was found to inhibit obesity in mice caused by high-fat diet [14], particularly, obesity has been generally considered to be inseparable from diabetic pregnancy-eclampsia [15].

The adverse environment in the body of mother with GDM affects the fetus through the placenta, and the material exchange between mother and fetus principally occurs in the placental trophoblast [16]. It happens that CTRP6 is expressed in the gestational trophoblast cells according to the human protein atlas (HPA) website (https://www.proteinatlas.org/), which is dedicated to providing information on the tissue and cell distribution of all 24,000 human proteins [17] (Figure 1a).

Therefore, this study put forward the hypothesis that CTRP6 may play a role in GDM. High glucose was used to induce trophoblast cells to establish an in vitro model. This paper explored the effects of CTRP6 on the cell phenotypes, covering cell proliferation, invasion and migration and initially explored the mechanism.

Methods

Cell culture and grouping

Human chorionic trophoblast cells (HTR-8/SVneo cells) were obtained from American Type Culture Collection (ATCC) and can be used for the study of placental function and trophoblast biology [18].

![Figure 1](https://www.proteinatlas.org/)

**Figure 1.** (a) Expression levels of CTRP6 in different types of cells from the analysis result of HPA website. (b) Cell viability in each group was assessed using a CCK-8 assay. Expression levels of CTRP6 in each group of cells were determined using (c) Western blotting and (d) RT-qPCR. Expression levels of PPARγ were determined using (e) Western blotting and (f) RT-qPCR. *p < 0.05, **p < 0.01, ***p < 0.001.
The cells grew adherently, and the culture condition was RPMI 1640 medium (5.5 mM glucose; Gibco, Thermo Fisher Scientific, China): FBS: penicillin/streptomycin with 100:10:1, and the incubator was adjusted to 37°C, 5% CO₂ condition. The cells were randomly divided into a control group and high glucose groups, each containing the final concentration of D-glucose: the control group (5.5 mM); the high glucose group (10, 20, 30 mM) [19].

**Cell transfection and grouping**

Cells were seeded in a six-well plate at a density of $3 \times 10^5$, and transfection was performed [20] when cell density reached 50%~60% next day. CTRP6 knockdown was performed with the pLKO.1-short hairpin vector (shRNA-CTRP6-1/2), whereas non-targeted shRNA was as the negative control (shRNA-NC; Vectorbuilder Biotechnology, Guangzhou, China). Target sequences of shRNAs were as follows: shRNA-CTRP6-1, 5′-GATGTGTTGAGATCCCTATGGT-3′; shRNA-CTRP6-2, 5′-GGACCTTCTCAACTTGGAAAT-3′; shRNA-NC, 5′-CAACAAAGATGAGGACACCACAA-3′ Peroxisome proliferator-activated receptor gamma (PPARγ) overexpression (Ov) was performed with a pcDNA3.1 vector (Ov-PPARγ), whereas the empty vector was set as the negative control (Ov-NC; Fenghui Biotechnology, Hunan, China). Cells were transfected with 10 nM shRNAs and pcDNAs using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, China) at 37°C, according to the manufacturer’s protocol. Following 4–6 h of transfection, the wells were washed twice with PBS, and then filled with RPMI-1640 medium containing 10% FBS to continue the culture for 48 h. Afterward, the cells were divided into a control group, high glucose group (30 mM), and transfection groups.

**CCK-8 assay**

The cells were seeded in a 96-well plate at a density of $3 \times 10^3$ cells/well. Following the culture maintained for 72 h, 10 µl of CCK-8 reagent (Beyotime Biotechnology, Shanghai, China) was added, and cells were continued to be incubated at 37°C for 1 h in the dark. The absorbance of each well at a wavelength of 450 nm was measured using a microplate reader (Molecular devices, Shanghai, China) [21].

**Reverse transcription-quantitative PCR (RT-qPCR)**

Total RNA was extracted from cells using TRIzol® (Invitrogen; Thermo Fisher Scientific, China) on ice for 15 min. The purity of the RNA was evaluated using a NanoDrop™ One Spectrophotometer (Thermo Fisher Scientific, China). Following reverse transcription of RNA into cDNA product with PrimeScript RT reagent kit (Takara Biotechnology, Dalian, China), SYBR Green Realtime PCR Master Mix kit (TOYOBO, Shanghai, China) was used according to the manufacturer’s protocol for qPCR. The thermocycling condition was as follows: Initial denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 2 sec and annealing at 60°C for 20 sec, and extension at 70°C for 10 sec. The normalization method was adopted with GADPH as the internal reference, and $2^{-\Delta\Delta C_{q}}$ method [22] was used to perform relative quantification. The primers (5′-3′) used are as follows: CTRP6, forward: CCATCCTGGAGGGTACAAAGG, reverse: AG TAATGGCCTGTCGCAAGG; PPARγ, forward: AATGGAAGACCCTCCACT, reverse: GGTA CTCCTGAACTTTCAGGTC; GAPDH, forward: GAGGCGAGATCCCTCMAAM, reverse: GCT GTTGCTACCATCCTGAG.

**Western blot analysis**

Protein was extracted from cells on ice with pre-cooled RIPA lysis buffer (contains protease inhibitors; Beyotime Biotechnology) for 10 min, and then quantified using a BCA assay kit (Abcam, Shanghai, China). Protein samples (30 µg/lane) were separated by 10% SDS-PAGE at 120 V and transferred to PVDF membranes (Millipore, Thermo Fisher Scientific) at 280 mV for 90 min. The membranes were first blocked with 5% skimmed milk for 2 h at room temperature. Afterward, they were incubated with diluted primary antibodies against CTRP6 (ab36898; 1:500), PPARγ (ab178860; 1:1,000), Bcl2 (ab32124; 1:1,000), Bax (ab32503; 1:1,000), Cleaved caspase3 (ab32042; 1:500) and GAPDH (ab181602; 1:10,000) at 4°C overnight followed by HRP-conjugated goat anti-rabbit IgG secondary
antibody (ab6721; 1:10,000; all Abcam) at room temperature for 1 h. The chemiluminescence reaction was performed using an ECL kit (Yeasen BioTechnology, Shanghai, China), and densitometry was analyzed using the ImageJ software (v1.8; National Institutes of Health) [23].

**TUNEL assay**

Cells were seeded into a 24-well plate at a density of 2 × 10^5 cells/well and cultured until they reached ~80% confluence. The operation was conducted using the TUNEL kit (Beyotime Biotechnology) according to the manufacturer’s instructions. Following the cover glass was sealed, the results were observed under a fluorescence microscope (magnification, x200; Olympus Corporation, Japan) [24].

**Wound healing assay**

Cells were seeded into a 6-well plate at a density of 5 × 10^5 cells/well until reaching ~80% confluence. A gentle scrape on the well surface was performed with a 200-µl pipette tip. The wells were washed with PBS to remove free cells. Following culture in serum-free RPMI-1640 medium at 37°C for 24 h, images of the wound area were captured at 0/24 h under an inverted microscope (magnification, x100; Nikon Corporation, Japan) [25].

**Transwell assay**

The Matrigel (BD Biosciences) was taken out from −20°C and melted on ice, and quickly diluted with serum-free RPMI-1640 medium at a ratio of 1:4. 50 µl of the diluted Matrigel was added to the upper chamber of the Transwell (Corning, Merck KGaA, Germany) for dry at 37°C for 10 h. The cells were resuspended in serum-free RPMI-1640, and the cell density was adjusted to 4 × 10^4 cells/ml. 100 µl cell suspension was added into the upper chamber, and 500 µl RPMI-1640 containing 20% FBS was added into lower chamber. Following incubation at 37°C for 24 h, the non-invaded cells in the upper chamber were gently wiped away with a wet cotton swab. The cells on the submembrane surface were fixed with 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet for 10 min at room temperature. The results were observed under an inverted microscope (magnification, x100; Nikon Corporation) [26].

**Statistical analysis**

Each cellular experiment was repeated independently at least three times. Data were presented as the mean ± SD and processed using GraphPad Prism 8.0 (GraphPad Software, San Diego, USA). Data were in accordance with the normal distribution by Shapiro-Wilk test [27], and comparisons were conducted using one-way ANOVA [28] followed by Tukey’s post hoc test [29]. P < 0.05 was considered to indicate a statistically significant difference.

**Results**

In the present study, CTRP6 and PPARγ were found to be upregulated in high glucose-induced cells. And CTRP6 knockdown could significantly elevate the abilities of cell viability, migration and invasion, and avoid cell apoptosis. In addition, PPARγ overexpression was found to restrain the protective effects of CTRP6 knockdown on the above aspects, indicating CTRP6 played a role in trophoblast cells via inhibiting PPARγ signaling.

**Expression levels of CTRP6 and PPARγ in high glucose induced-trophoblast cells**

CTRP6 was found to be expressed in gestation trophoblast from the analysis result of HPA website (Figure 1a). Human chorionic trophoblast cells (HTR-8/SVneo cells) were firstly divided into the control group and high glucose groups (10, 20, 30 mM). Cell viability in each group was assessed using a CCK-8 assay. Following induction with glucose, cell viability was found to be decreased in a concentration-dependent manner (Figure 1b). Next, the expression levels of CTRP6 in each group of cells were determined using RT-qPCR and Western blotting. The results revealed that CTRP6 expression level was upregulated accompanied with the increased concentration of glucose (Figure 1c-d). In addition, the expression levels of PPARγ were also upregulated depending on the elevated concentration of glucose (Figure 1e-f).
CTRP6 knockdown improves the viability, invasion and migration of high glucose induced-trophoblast cells

In order to explore the role of CTRP6 in high glucose induced-trophoblast cells, its expression was knocked down by transfection with shRNAs. The expression levels of CTRP6 in the control and the transfected cells were determined using RT-qPCR and Western blotting. According to the results, the expression level was lower in the shRNA-CTRP6-1 group compared with the shRNA-CTRP6-2 group (Figure 2a-b), hence, these cells transfected with shRNA-CTRP6-1 were used for the subsequent assays. Afterward, cells were divided into four groups: (Ⅰ) the control; (Ⅱ) high glucose (30 mM); (Ⅲ) high glucose (30 mM) + shRNA-NC; (Ⅳ) high glucose (30 mM) + shRNA-CTRP6. Cell viabilities of these groups of cells were determined using the CCK8 assay, and the results demonstrated that CTRP6 knockdown could upregulate the viability of high glucose induced-cells (Figure 2c). Meanwhile, cell apoptosis was determined using TUNEL assay and Western blotting. The fluorescence intensity was enhanced in the high glucose group compared with the control group, and that was downregulated in the CTRP6 knockdown group to a certain extent (Figure 2d-e). In addition, the Western blot

Figure 2. Expression levels of CTRP6 in the control and the transfected cells were determined using (a) Western blotting and (b) RT-qPCR. (c) Cell viability was determined using a CCK8 assay. Cell apoptosis was determined using (d–e) TUNEL assay and (f) Western blotting, magnification, x200. *p < 0.05, **p < 0.01, ***p < 0.001.
result revealed that the expression levels of Bax and cleaved caspase 3 were downregulated, whereas Bcl2 expression was upregulated arisen from CTRP6 knockdown (figure 2f). These indicated that CTRP6 knockdown could protect the aliveness of trophoblast cells from the injury caused by high glucose.

Moreover, the abilities of cell migration and invasion were assessed using wound healing and Transwell assays. The result of wound healing assay displayed that high glucose caused the inhibited cell migration and CTRP6 knockdown promoted it (Figure 3a). Coincidentally, CTRP6 knockdown likewise recovered the inhibiting effect of high glucose on cell invasion from the result of Transwell assay (Figure 3b). To sum up, CTRP6 knockdown improved cell survival, invasion and migration of trophoblast cells which were subjected to high glucose.

CTRP6 knockdown inhibits PPARγ expression and improves the viability, invasion and migration of high glucose induced-trophoblast cells by inhibiting PPARγ

The expression levels of PPARγ in the four groups of cells mentioned above were determined using Western blotting. Its expression was upregulated in high glucose group and downregulated in the CTRP6 knockdown group, indicating insufficient CTRP6 expression may also cause a decline in the expression of PPARγ (Figure 4a). Subsequently, PPARγ overexpression was established by transfection, and the efficacy was verified using RT-qPCR and Western blotting. The results of these two assays both revealed that PPARγ was highly expressed in the transfected cells (Figure 4b-c). Following cells were divided into five groups: 1) the control; 2) high glucose (30 mM); 3) high glucose (30 mM) + shRNA-CTRP6; 4) high glucose (30 mM) + shRNA-CTRP6 + Ov-NC; 5) high glucose (30 mM) + shRNA-CTRP6 + Ov-PPARγ, cell viability was determined in these five groups using the CCK8 assay. The result indicated that PPARγ overexpression downregulated high glucose-induced cell viability, breaking the effect of CTRP6 knockdown on the viability (Figure 4d). Furthermore, cell apoptosis was determined similarly as aforementioned. Focusing on the results of the fifth group, PPARγ overexpression significantly promoted cell apoptosis, which is equivalent to reversing the impact of CTRP6 knockout on cell survival (Figure 4e-g).

Finally, cell migration and invasion was also assessed using wound healing and Transwell assay. The results suggested that PPARγ overexpression could not only suppress cell migration but also inhibit the invasion (Figure 5a-d). These results indicated that CTRP6 knockdown improved the invasion and migration of high glucose.

Figure 3. The ability of cell migration and invasion was assessed using (a) wound healing and (b) Transwell assay, magnification, x100. ***p < 0.001.
glucose induced-trophoblast cells by inhibiting PPARγ expression.

**Discussion**

GDM is a familiar perinatal comorbidity that influences maternal transformation, placenta formation and fetal development. It is also one of the predictors of long-term type 2 diabetes in pregnant women and their offspring [5]. Those with severe GDM or poor control of blood glucose may ultimately suffer from some adverse pregnancy outcomes, such as hypertension of pregnancy, premature delivery, stillbirth, fetal development and giant babies [30]. Therefore,
reasonable control of the condition and blood glucose can greatly reduce the impact on the health of mothers and children. During pregnancy, the placenta is a highly specific organ, it not only has the functions of supplying nutrients to the fetus, exchanging gas and removing metabolites, but also has immune and endocrine functions [31]. The formation of placenta principally depends on the extra-chorionic trophoblast to invade the membrane, and trophoblast cells serve as the first barrier between the mother and the fetus; its proliferation, differentiation, invasion, and apoptosis are associated with the normality of the placenta and the development of fetus [32]. Moreover, based on the direct correlation between trophoblast cells and the mother, the maternal blood glucose alterations directly influence the function of trophoblast cells. The trophoblast cells are the first to be involved and undergo various pathological changes to cope with the high glucose stress environment [33,34].

Therefore, this study selected trophoblast cells as a model to study the regulatory functions of CTRP6. As aforementioned, the phenotype of trophoblast cells is intimately relevant to fetal development [32]. Therefore, following confirming that the expression level of CTRP6 was upregulated in high glucose-induced cells, its effects on cell proliferation, migration and invasion were studied through silencing its expression. The results demonstrated that CTRP6 knockdown could maintain the viability of cells stimulated by high glucose, inhibit their apoptosis, and alleviate the inhibitory effects of high glucose on cell migration and invasion. Hence, these findings indicate that inhibiting CTRP6 expression may reduce the adverse effects on fetal development under high glucose condition. A clinical report revealed that compared with healthy individuals, serum CTRP6 levels in obese individuals were significantly upregulated. More importantly, the
receiver operating characteristic curve results suggested that CTRP6 levels were associated with IR [35]. In addition, a previous study found that CTRP6 knockdown could suppress the inflammation, oxidative stress and extracellular matrix accumulation in high glucose-induced glomerular mesangial cells, which provides a basis for CTRP6 to be applied in the treatment of diabetic nephropathy [36].

Furthermore, CTRP6 overexpression was reported to activate the PPARγ signal to relieve hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats [37]. And its knockdown was deemed to inhibit fat production in 3T3-L1 adipocytes through PPARγ signaling [38]. These indicated that PPARγ might act as the downstream target of CTRP6. Especially, a previous study revealed that PPARγ expression was upregulated in GDM placental tissue and trophoblast cells under high glucose environment [39]. Herein, following the determination of upregulated PPARγ expression level in high glucose-induced trophoblast cells, the effects of PPARγ on cell phenotype were studied by urging it to overexpress. The results in this study suggested that PPARγ overexpression reversed the influences of CTRP6 knockdown on cell phenotype. In other words, PPARγ overexpression could suppress cell viability, migration and invasion, and promote cell apoptosis, indicating CTRP6 play a role in altering the phenotype of high glucose-induced trophoblast cells through regulating PPARγ expression. This article proposes for the first time that CTRP6 affects GDM through PPARγ signaling. However, this study is limited to the cellular level, clinical samples will be collected for in-depth research in the future.

**Conclusion**

To sum up, the present study has found that CTRP6 knockdown promotes the viability, invasion and migration of high glucose induced-trophoblast cells via inhibiting PPARγ expression. The findings of the present study may promote CTRP6 as a biomarker or therapeutic target for the treatment of GDM.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This study was supported by Beijing Haidian District health development scientific research and cultivation plan (HP2021-05-50602); Youth fund of Beijing Shijitan Hospital Affiliated to Capital Medical University (2019-q20).

**Availability of data and materials**

The datasets used and/or analysed during the present study are available from the corresponding author on reasonable request.

**Authors’ contributions**

JZ and WB made contributions to content design and participated in the experiments; JZ analyzed the data and draft the manuscript; WB examined the data and critically revised the manuscript for important intellectual content. Both of them confirmed the authenticity of all the raw data and approved the final manuscript.

**References**

[1] American College of Obstetricians and Gynecologists Committee on Practice Bulletins. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol. 2018 Feb;131(2):e49–e64.

[2] de Gennaro G, Palla G, Battini L, et al. The role of adipokines in the pathogenesis of gestational diabetes mellitus. Gynecol Endocrinol. 2019 Sep;35(9):737–751.

[3] Chiefari E, Arcidiacono B, Foti D, et al. Gestational diabetes mellitus: an updated overview. J Endocrinol Invest. 2017 Sep;40(9):899–909.

[4] Szmuliowicz ED, Josephson JL, Metzger BE. Gestational diabetes mellitus. Endocrinol Metab Clin North Am. 2019 Sep;48(3):479–493.

[5] Johns EC, Denison FC, Norman JE, et al. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018 Nov;29(11):743–754.

[6] Plows JF, Stanley JL, Baker PN, et al. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018 Oct 26;19(11):11.

[7] Pérez-Pérez A, Vilarino-Garcia T, Guadix P, et al. Leptin and nutrition in gestational diabetes. Nutrients. 2020 Jul 2;12(7):1970.

[8] Radzicka S, Pietryga M, Iciek R, et al. The role of visfatin in pathogenesis of gestational diabetes (GDM). Ginekol Pol. 2018;89(9):518–521.

[9] Si Y, Fan W, Sun L. A review of the relationship between CTRP family and coronary artery disease. Curr Atheroscler Rep. 2020 May 28;22(6):22.

[10] Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, et al. Molecular, biochemical and functional characterizations
of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J. 2008 Dec 1;416(2):161–177.

[11] Sadeghi A, Fadai R, Moradi N, et al. Circulating levels of C1q/TNF-α-related protein 6 (CTRP6) in polycystic ovary syndrome. IUBMB Life. 2020 Jul;72 (7):1449–1459.

[12] Hano K, Hatano K, Saigo C, et al. An adiponectin paralog protein, CTRP6 decreased the proliferation and invasion activity of oral squamous cell carcinoma cells: possible interaction with laminin receptor pathway. Mol Biol Rep. 2019 Oct;46 (5):4967–4973.

[13] Dong X, Hu H, Fang Z, et al. CTRP6 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration. Biomed Pharmacother. 2018 Jul;103:844–850.

[14] Wu W, Zhang J, Zhao C, et al. Lentivirus-mediated CTRP6 silencing ameliorates diet-induced obesity in mice. Exp Cell Res. 2018 Jun 1;367(1):15–23.

[15] Yen IW, Lee CN, Lin MW, et al. Overweight and obesity are associated with clustering of metabolic risk factors in early pregnancy and the risk of GDM. PloS One. 2019;14(12):e0225978.

[16] Knöfler M, Haider S, Saleh L, et al. Human placenta and trophoblast development: key molecular mechanisms and model systems. Cell Mol Life Sci. 2019 Sep;76 (18):3479–3496.

[17] Thul PJ, Åkesson L, Wiking M, et al. A subcellular map of the human proteome. Science (New York, NY). 2017 May 26;356(6340):6340.

[18] Msheik H, Azar J, El Sabeh M, et al. HTR-8/SVneo: a model for epithelial to mesenchymal transition in the human placenta. Placenta. 2020 Jan 15;90:90–97.

[19] Liu L, Zhang J, Liu Y. MicroRNA-1323 serves as a biomarker in gestational diabetes mellitus and aggravates high glucose-induced inhibition of trophoblast cell viability by suppressing TP53INP1. Exp Ther Med. 2021 Mar;21(3):230.

[20] Wang Q, Lu X, Li C, et al. Down-regulated long non-coding RNA PVT1 contributes to gestational diabetes mellitus and preeclampsia via regulation of human trophoblast cells. Biomed Pharmacother. 2019 Dec;120:109501.

[21] Zhang L, Zhao F, Li C, et al. Hypomethylation of DNA promoter upregulates ADAMTS7 and contributes to HTR-8/SVneo and JEG-3 cells abnormalities in pre-eclampsia. Placenta. 2020 Apr;93:26–33.

[22] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001 Dec;25(4):402–408.

[23] Wang Y, Zhang L, Zhou X. Activation of Nrf2 signaling protects hypoxia-induced HTR-8/SVneo cells against ferroptosis. J Obstet Gynaecol Res. 2021 Nov;47 (11):3797–3806.

[24] Li J, Tong C, Xu P, et al. QSOX1 regulates trophoblastic apoptosis in preeclampsia through hydrogen peroxide production. J Matern Fetal Neonatal Med. 2019 Nov;32(22):3708–3715.

[25] Zhang X, Li BY, Fu LJ, et al. Stomatin-like protein 2 (SLP2) regulates the proliferation and invasion of trophoblast cells by modulating mitochondrial functions. Placenta. 2020 Oct;100:13–23.

[26] Fang YN, Huang ZL, Li H, et al. Highly expressed miR-182-5p can promote preeclampsia progression by degrading RND3 and inhibiting HTR-8/SVneo cell invasion. Eur Rev Med Pharmacol Sci. 2018 Oct;22 (20):6583–6590.

[27] Vetter TR. Fundamentals of research data and variables: the devil is in the details. Anesth Analg. 2017 Oct;125(4):1375–1380.

[28] Wei P, Ru D, Li X, et al. Exposure to environmental bisphenol A inhibits HTR-8/SVneo cell migration and invasion. J Biomed Res. 2020 Jun 30;34(5):369–378.

[29] Hazra A, Gogtay N. Biostatistics series module 3: comparing groups: numerical variables. Indian J Dermatol. 2016 May-Jun;61(3):251–260.

[30] Pan JP, Liang SS, Huang MY, et al. Obstetric and neonatal outcomes after frozen-thawed embryos transfer with laser-assisted hatching: a retrospective cohort study. Arch Gynecol Obstet. 2021 Aug 14. DOI:10.1007/s00404-021-06153-0.

[31] Rolfo A, Nuzzo AM, De Amicis R, et al. Fetal-maternal exposure to endocrine disruptors: correlation with diet intake and pregnancy outcomes. Nutrients. 2020 Jun 11;12(6). DOI:10.3390/nu12061744.

[32] West RG, Ming H, Logsdon DM, et al. Dynamics of trophoblast differentiation in peri-implantation-stage human embryos. Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22635–22644.

[33] Lorenzo AR, Moreli JB, de Macedo Melo R, et al. Stromal cell-derived factor (SDF) 2 and the endoplasmic reticulum stress response of trophoblast cells in gestational diabetes mellitus and in vitro hyperglycaemic condition. Curr Vasc Pharmacol. 2021;19(2):201–209.

[34] Blundell C, Tess ER, Schanzer AS, et al. A microphysiological model of the human placental barrier. Lab Chip. 2016 Aug 2;16(16):3065–3073.

[35] Liao X, Liu S, Tang X, et al. Circulating CTRP6 levels are increased in overweight or obese Chinese individuals and associated with insulin resistance parameters: a pilot study. Exp Clin Endocrinol Diabetes. 2021 Jul;129(7):535–541.

[36] Xu E, Yin C, Yi X, et al. Knockdown of CTRP6 inhibits high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation in mesangial cells
through regulating the Akt/NF-κB pathway. Clin Exp Pharmacol Physiol. 2020 Jul;47(7):1203–1211.

[37] Chi L, Hu X, Zhang W, et al. Adipokine CTRP6 improves PPARγ activation to alleviate angiotensin II-induced hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats. Biochem Biophys Res Commun. 2017 Jan 22;482(4):727–734.

[38] Wu WJ, Mo DL, Zhao CZ, et al. Knockdown of CTRP6 inhibits adipogenesis via lipogenic marker genes and Erk1/2 signalling pathway. Cell Biol Int. 2015 May;39(5):554–562.

[39] Suwaki N, Masuyama H, Masumoto A, et al. Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy. Placenta. 2007 Apr;28(4):315–323.